Table 5. Anthropometric data of the subjects (safety set).
| Placebo Group (n = 64) | Bio-Germanium Group (n = 66) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline | Follow-up1 | Δ | Baseline | Follow-up | Δ | P | |
| Systolic BP (mmHg) | 115.53 ± 12.78 | 114.73 ± 12.69 | -0.71 ± 10.18 | 116.24 ± 11.78 | 116.35 ± 13.14 | 0.11 ± 11.47 | 0.669 |
| Diastolic BP (mmHg) | 70.20 ± 8.83 | 70.11 ± 8.99 | -0.03 ± 8.09 | 70.77 ± 8.19 | 71.06 ± 9.18 | 0.29 ± 8.32 | 0.825 |
| Heart Rate (bpm) | 77.41 ± 8.68 | 78.06 ± 9.44 | 0.75 ± 8.11 | 77.08 ± 10.58 | 75.77 ± 10.14 | -1.30 ± 8.71 | 0.170 |
| Body Temperature (°C) | 36.20 ± 0.16 | 36.13 ± 0.14 | -0.07 ± 0.19 | 36.20 ± 0.16 | 36.14 ± 0.14 | -0.05 ± 0.21 | 0.633 |
| Weight (kg) | 61.08 ± 10.17 | 60.71 ± 10.41 | -0.14 ± 1.13 | 60.88 ± 8.68 | 60.92 ± 8.72 | 0.04 ± 1.03 | 0.340 |
The data represent the mean ± standard deviation.
Δ represents the change from baseline at follow-up.
P-values were derived from an independent t-test for Δ between groups.
1 Safety set analysis of the placebo group at follow-up consisted of 63 participants, excluding one subject’s voluntary dropout.